Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Capitalization 389B 291M 22.3B P/E ratio 2024 *
11.2x
P/E ratio 2025 * 10.2x
Enterprise value 383M 287K 21.99M EV / Sales 2024 *
1.95x
EV / Sales 2025 * 1.5x
Free-Float
67.19%
Yield 2024 *
1.13%
Yield 2025 * 1.13%
More valuation ratios * Estimated data
Dynamic Chart
SphingoTec GmbH Introduces Kidney Function Biomarker penKid Together with Boditech Med Inc. At the 42nd AKI & CRRT Course in Vicenza CI
4TEEN4 Pharmaceuticals GmbH announced that it has received funding from Boditech Med Inc. CI
Boditech Med Inc. and SphingoTec GmbH Enter into Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid CI
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022. CI
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022. CI
Boditech Med Inc.'s Equity Buyback announced on September 29, 2022, has expired with 496,620 shares, representing 2.21% for KRW 4,994.56 million CI
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022. CI
Boditech Med Inc. and SphingoTec GmbH Enters into Non-Exclusive Royalty-Bearing License Agreement CI
Boditech Med Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
Boditech Med Inc. authorizes a Buyback Plan. CI
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on December 14, 2021. CI
Boditech Med Inc.'s Equity Buyback announced on December 14, 2021, has expired with 297,901 shares, representing 1.31% for KRW 4,987.06 million. CI
Novo Integrated Sciences, Boditech Med Sign Memorandum of Understanding for Distribution of Diagnostic Technologies MT
More news
1 day+3.45%
1 week-3.75%
Current month-3.12%
1 month-9.24%
3 months+1.14%
6 months+16.46%
Current year-13.71%
More quotes
1 week
16 410.00
Extreme 16410
18 000.00
1 month
16 410.00
Extreme 16410
21 050.00
Current year
13 400.00
Extreme 13400
21 050.00
1 year
13 400.00
Extreme 13400
22 150.00
3 years
8 420.00
Extreme 8420
22 150.00
5 years
8 250.00
Extreme 8250
39 700.00
10 years
7 610.00
Extreme 7610
58 181.82
More quotes
Director TitleAgeSince
Chief Executive Officer 63 31/12/97
Chief Tech/Sci/R&D Officer 68 31/12/08
Director/Board Member 51 31/12/16
Manager TitleAgeSince
Chief Executive Officer 63 31/12/97
Director/Board Member 69 27/07/15
Director/Board Member 58 27/07/15
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+3.45%-3.75%-14.54%-6.89%280M
-0.80%+5.59%-28.60%-57.92%17.22B
+1.65%+11.12%-39.81%-69.99%2.97B
-3.72%-5.16%+60.44%-28.02%1.47B
+2.35%-2.88%+36.41%+199.30%1.4B
+1.77%-4.77%+1.50% - 1.23B
-0.58%+1.98%+53.42%-45.81%1B
+2.66%+4.96%-23.65% - 767M
-0.62%-0.23%-39.08%-66.28%730M
-3.95%+5.47%+54.76%-39.16%668M
Average +0.22%+1.78%+6.08%-14.35% 2.77B
Weighted average by Cap. -0.34%+4.62%-15.48%-42.32%
See all sector performances

Financials

2024 *2025 *
Net sales 149B 112M 8.57B 174B 130M 9.98B
Net income 37.8B 28.27M 2.17B 41.3B 30.89M 2.37B
Net Debt -98.3B -73.53M -5.64B -128B -95.52M -7.33B
More financial data * Estimated data
Logo Boditech Med Inc.
Boditech Med Inc is a Korea-based company principally engaged in the manufacture and sale of medical equipment. The Company is engaged in the manufacture and sale of antigen diagnostic kits and other products. In addition, the Company is engaged in the manufacture and sale of cancer diagnostic kit, drug concentration diagnostic kit and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 1998 and is located in Chuncheon-si, Gang-won-do, South Korea.
Employees
492
More about the company
Date Price Change Volume
11/09/24 17,690.00 +3.45% 106,494
10/09/24 17,100.00 +1.48% 32,731
09/09/24 16,850.00 +0.42% 64,027
06/09/24 16,780.00 -1.58% 122,913
05/09/24 17,050.00 -3.23% 136,696

End-of-day quote Korea S.E., September 10, 2024

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17,690.00KRW
Average target price
24,500.00KRW
Spread / Average Target
+38.50%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A206640 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW